News from oramed pharmaceuticals inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 24, 2014, 14:30 ET

Oramed Pharmaceuticals Presents Data from Phase IIa Trial with ORMD-0801 in Type 2 Diabetes at the 2014 Diabetes Summit

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug...

Apr 10, 2014, 08:10 ET

Oramed Granted Patent in Hong Kong for Oral Administration of Insulin

 Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug...

Mar 27, 2014, 08:45 ET

Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral...

Mar 11, 2014, 08:30 ET

Oramed Granted its 3rd Patent in Australia for Oral Administration of Exenatide

 Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...

Mar 06, 2014, 08:20 ET

Oramed to Present at Upcoming Conferences

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral...

Mar 03, 2014, 08:20 ET

Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral...

Feb 10, 2014, 09:47 ET

Oramed Submits Phase 2a Protocol to FDA for the Treatment of Type 1 Diabetes with its Oral Insulin Capsule

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug...

Jan 30, 2014, 04:00 ET

Oramed Announces Successful FDA Phase 2a Clinical Trial Results

 Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, announced today results from its Phase 2a clinical...

Jan 27, 2014, 09:10 ET

Oramed to Announce Results of its Phase 2a Clinical Trial for Oral Insulin on January 30th at the Tel Aviv Stock Exchange

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it will...

Jan 02, 2014, 08:20 ET

Oramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of Proteins

 Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it...

Dec 24, 2013, 21:12 ET

Oramed to Raise $15,800,000 in Registered Direct Offering

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has entered into definitive...

Dec 20, 2013, 07:30 ET

Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug...

Dec 10, 2013, 10:37 ET

Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel

Oramed Pharmaceuticals Inc. (NASDAQCM:ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral...

Nov 19, 2013, 09:57 ET

Oramed Receives Patent in the European Union for the Oral Delivery of Insulin

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the European Patent...

Nov 12, 2013, 10:12 ET

Oramed Announces Last Patient Out in Phase 2a FDA Trial of its ORMD-0801 Oral Insulin Capsule

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral...

Oct 03, 2013, 11:13 ET

Oramed Granted Patents in Japan and Canada for its POD™ Technology for the Oral Delivery of Proteins

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has...

Sep 25, 2013, 08:10 ET

Oramed to Participate in Barclays' Israel Biotech Corporate Day in Zurich on September 30, 2013

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been...

Sep 17, 2013, 08:10 ET

Oramed's Platform Technology in Oral Delivery of Proteins Receives Patent in Russia

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been...

Sep 10, 2013, 08:10 ET

Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has...

Sep 03, 2013, 08:10 ET

Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has...